Renal functions and tissues in diabetic nephropaty models is improved through D-532 oral administration.
The number of dialysis patients continues to increase, and it is known that applox. 40% of the patients requiring dialysis in Japan were ordinally those with diabetic nephropathy (DN). The treatment for DN is often symptomatic by controling blood sugar and blood pressure, and to date, no effective therapeutic agent for curative treatment has been developed. This invention discloses a 1, 3-dioxolane compounds D-532 and the derivertives thereof, which inhibits the function of the glucose-responsive transcription factor ChREBP (Carbohydrate responsive element binding protein), for DN treatment. D-532 was found by ordinally constructed high-throughput screening based on ChREBP reporter assay with applox. 7,000 of compound library in Tohoku University (Fig.1). Synthesized analogs and isomers thereof were also tested and showed inhibitory effect against ChREBP function, although D-532 showed the highest activity (Data not shown). The expression of ChREBP target genes were suppressed by D-532 administration for DN animal model (Fig.2). Urinary albumin excretion and blood creatinine were also improved in DN animals with D-532 (Fig.3). Further, the disappearance of foot process in glomerulus, which is often observed in DN kidney, was suppressed (Data not shown), suggesting that D-532 may act directly to renal tissue and show the effects above.
Inquire About This Product
basic information
For details, please contact us or refer to the PDF.
Price range
Delivery Time
Applications/Examples of results
For details, please contact us or refer to the PDF.
catalog（1）
Download All Catalogs
Company information
The revenue generated from technology transfer is reinvested into universities and researchers as new research funding, which is used to create further research outcomes. To ensure the smooth operation of this cycle, known as the "Intellectual Creation Cycle," we will actively promote technology transfer. The types of seeds we handle include patents, know-how, databases, and programs. We have established a collaborative framework by concluding basic technology transfer agreements with the following universities (as of April 1, 2026): - Tohoku University - Hirosaki University - Iwate University - Akita University - Fukushima University - Yamagata University - Tohoku Gakuin University - Iwate Medical University - Fukushima Medical University - Aizu University - Miyagi University - Hokkaido University - Muroran Institute of Technology - Showa Medical University - Asahikawa Medical University
